GLP-1 Medications and Alzheimer’s Disease

GLP-1 medications have been talked about for years as possible protection for the brain, not just help for weight and blood sugar, and it is easy to see why people got hopeful. In late 2025, two large trials put the idea to a direct test in people with early Alzheimer’s disease. Here is how that went and what it does and does not mean for you. This is general education, not medical advice.

Why researchers were hopeful

GLP-1 receptors are found in parts of the brain, and animal and cell studies suggested that activating them might calm inflammation and support nerve cells. Some observational studies in people with type 2 diabetes also hinted at lower dementia rates among those taking these medications. Observational data cannot show cause and effect, because people who are prescribed a medication differ from those who are not in many ways. A randomized trial is the usual next step, and that is exactly what the EVOKE and EVOKE+ studies were.

How the two trials were set up

• Who took part: a combined 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed by a biomarker test.
• What they received: daily oral semaglutide or a placebo, on top of their usual care.
• How long: a main treatment phase of 104 weeks (two years), with a planned one-year extension.
• The main question: whether the medication slowed how quickly symptoms and daily functioning worsened, measured with a standard dementia rating scale.

The result

Novo Nordisk announced topline results on November 24, 2025. Semaglutide did not slow disease progression compared with placebo in either trial. The company reported that some Alzheimer’s-related biomarkers moved in a favorable direction, but that did not translate into better thinking, memory or daily function. The extension phase was discontinued. The medication was described as well tolerated, in line with its known safety record. More detailed data were presented at a major Alzheimer’s conference in December 2025, and an abstract in 2026 reported the same overall pattern for the main and key secondary measures.

What this means for you

• It was a clear answer to a specific question. In people who already have early Alzheimer’s, two years of oral semaglutide did not change the course of the disease. A clear answer is real progress, because it points researchers toward better ideas.
• It does not cover everything. These trials did not test whether GLP-1 medications might lower the chance of developing dementia in the first place, or whether other forms or doses would behave differently.
• Brain protection is not a reason to start or stop. The reasons people use these medications are the established ones, such as weight and blood sugar. Questions about a medication belong with your prescriber.
• Biomarker changes are not benefits. A number on a test improving is encouraging, but the real test is how people feel and function.

Everyday habits still count

Here is the cheerful part: large reviews of dementia risk keep returning to ordinary things you can do. Staying physically active, sleeping well, keeping blood pressure and blood sugar in check, not smoking, and staying connected with other people all matter. Our guides to GLP-1 medications and kidney health, the SELECT heart trial and alcohol cravings show how research on these medications keeps widening, and how some promising ideas hold up while others do not. For a look at the pill versions, see our guide to oral GLP-1 medications.

Sources

• Novo Nordisk. Topline results from the EVOKE and EVOKE+ phase 3 trials of oral semaglutide in early Alzheimer’s disease, announced November 24, 2025 (details from the announcement as reported by Alzheimer Europe and NeurologyLive; the full paper was not read).
• EVOKE and EVOKE+ results presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, December 2025, and a 2026 American Academy of Neurology abstract by the investigators (as summarized in news coverage and conference listings).
• Alzheimer Europe. Results of EVOKE and EVOKE+ trials show no effect of oral semaglutide on Alzheimer’s disease progression.